Volume 68, Issue 5, Pages (November 2015)

Slides:

Advertisements

Similar presentations

Volume 69, Issue 5, Pages (May 2016)

Advertisements

Volume 61, Issue 5, Pages (May 2012)

Volume 62, Issue 4, Pages (October 2012)

Early Detection of Prostate Cancer in 2007

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Reversible, Non-Barrier Male Contraception: Status and Prospects

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 61, Issue 6, Pages (June 2012)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Volume 60, Issue 5, Pages (November 2011)

Volume 54, Issue 6, Pages (December 2008)

Volume 54, Issue 4, Pages (October 2008)

Volume 66, Issue 4, Pages (October 2014)

Volume 199, Issue 1, Pages (January 2018)

Volume 64, Issue 4, Pages (October 2013)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Prostate Cancer Epidemic in Sight?

Volume 71, Issue 2, Pages (February 2017)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 68, Issue 4, Pages (October 2015)

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 52, Issue 3, Pages (September 2007)

Volume 54, Issue 4, Pages (October 2008)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 4, Pages (October 2016)

Prostate Cancer Detection: A View of the Future

Volume 54, Issue 5, Pages (November 2008)

Volume 64, Issue 5, Pages (November 2013)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 66, Issue 5, Pages (November 2014)

Counselling the Prostate Cancer Patient

Volume 66, Issue 6, Pages (December 2014)

Prostate Cancer Epidemic in Sight?

Volume 65, Issue 2, Pages (February 2014)

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 62, Issue 6, Pages (December 2012)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Testicular Cancer Variations in Time and Space in Europe

Optimal Testosterone Control and Eligard®

Neal Shore European Urology Supplements

Volume 71, Issue 4, Pages (April 2017)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 69, Issue 5, Pages (May 2016)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 54, Issue 5, Pages (November 2008)

Improving Flexibility and Quality of Life for Your Patients: A Must?

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Bertrand Tombal, Richard Berges

Volume 51, Issue 5, Pages (May 2007)

Volume 69, Issue 4, Pages (April 2016)

Presentation transcript:

Volume 68, Issue 5, Pages 787-794 (November 2015) Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiri Heracek, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Benoit Baron, Mohammad Hirmand, Matthew R. Smith European Urology Volume 68, Issue 5, Pages 787-794 (November 2015) DOI: 10.1016/j.eururo.2015.01.027 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 (A) Mean percentage change in prostate-specific antigen from baseline and (B) mean prostate-specific antigen level by week. Bars show standard deviation. European Urology 2015 68, 787-794DOI: (10.1016/j.eururo.2015.01.027) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Mean percentage change in luteinizing hormone and testosterone from baseline to week 49. European Urology 2015 68, 787-794DOI: (10.1016/j.eururo.2015.01.027) Copyright © 2015 European Association of Urology Terms and Conditions